Published :
Tables : 200
Figures : 30
Category : Healthcare
No. of Pages : 200
Report Code : HC-1297
Nuclear Medicine or Radiopharmaceuticals Market Introduction Nuclear Medicine or Radiopharmaceuticals Market is estimated to value over USD 5.7 billion by 2027 end and register a CAGR of over 4.5% during the forecast period 2020 to 2027. Market research has predicted that the rise of ailments such as Parkinson's, Alzheimer’s, Cancer and Cardiac failure are reasons which have contributed to the nuclear medicine/radiopharmaceuticals market growth in the forecast period. New strides within neurological applications and major shifts in new products by various companies are aiding the demand for the affordability of radiopharmaceuticals. Imaging processes in nuclear medicine are non-invasive and can be used for treating a number of diseases, such as cancers, neurological disorders and cardiovascular diseases. Moreover, surplus investment in healthcare, a need for adequate healthcare facilities and the non-invasive aspects of the process are factors that have pushed for the market growth. The radiopharmaceuticals and nuclear medicine markets is further stimulated by innovations in radiotracers and radioisotopes. However, the lack of reimbursement policies, the short life span of radiopharmaceuticals and the stringent policies laid out by governing bodies could pose potential threats to the market on a global scale. Nuclear medicine processes provide help in diagnosing diseases with precise and detailed results at an early stage, long before the symptoms occur. Nuclear medicine tests entails less pain and offers information regarding specific organs with very little radiation. This aids the physicians to treat illnesses such as thyroid, cancer and bone metastasis. The diagnostics segment has sub-segments that are known as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The SPECT segment is likely to dominate the radiopharmaceutical/nuclear medicine diagnostics market in the future owing to the reduced costs and greater availability. The therapeutics segment is further classified into alpha emitters, beta emitters, and brachytherapy isotopes. The beta emitters will be the foremost segment in the radiopharmaceutical therapeutics and nuclear medicine market. Some of the players operating in the radiopharmaceuticals and nuclear medicine market includes Cardinal Health Inc. Lantheus Medical Imaging Inc., GE Healthcare, Eczacibasi-Monrol Nuclear Products, IBA Molecular Imaging, Bayer Healthcare, Nordion Inc, Bracco Imaging S.p.A, Advanced Accelerator Applications S.A. Nuclear Medicine or Radiopharmaceuticals Market Segmentation: By Type Diagnostic Nuclear Medicine Spect Radiopharmaceuticals Tc-99m Tl-201 Ga-67 I-123 Other Spect Isotopes Pet Radiopharmaceuticals F-18 Ru-82 Other Pet Isotopes Therapeutic Nuclear Medicine Alpha Emitters Ra-223 Beta Emitters I-131 Y-90 Sm-153 Re-186 Lu-177 Other Beta Emitters Brachytherapy Isotopes I-125 Ir-192 Pd-103 Cs-131 Other Brachytherapy Isotopes By Application Diagnostic Applications Spect Applications Cardiology Lymphoma Neurology Thyroid Other Spect Applications Pet Applications Oncology Cardiology Neurology Other Pet Applications Therapeutic Applications Thyroid Bone Metastasis Lymphoma Endocrine Tumors Other Therapeutic Applications By Procedural Volume Diagnostic Procedures Spect Radiopharmaceuticals Pet Radiopharmaceuticals Therapeutic Procedures Beta Emitters Alpha Emitters Brachytherapy Isotopes By Region Europe North America Asia Pacific Rest of the World FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the nuclear medicine/pharmaceuticals market by type, by application, by procedural volume and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities) To forecast and evaluate micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world To record , evaluate and analyze competitive landscape mapping- technological advancements, product launches, expansions and mergers Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Nuclear Medicine or Radiopharmaceuticals Market is estimated to value over USD 5.7 billion by 2027 end and register a CAGR of over 4.5% during the forecast period 2020 to 2027.
Market research has predicted that the rise of ailments such as Parkinson's, Alzheimer’s, Cancer and Cardiac failure are reasons which have contributed to the nuclear medicine/radiopharmaceuticals market growth in the forecast period. New strides within neurological applications and major shifts in new products by various companies are aiding the demand for the affordability of radiopharmaceuticals. Imaging processes in nuclear medicine are non-invasive and can be used for treating a number of diseases, such as cancers, neurological disorders and cardiovascular diseases.
Moreover, surplus investment in healthcare, a need for adequate healthcare facilities and the non-invasive aspects of the process are factors that have pushed for the market growth. The radiopharmaceuticals and nuclear medicine markets is further stimulated by innovations in radiotracers and radioisotopes. However, the lack of reimbursement policies, the short life span of radiopharmaceuticals and the stringent policies laid out by governing bodies could pose potential threats to the market on a global scale.
Nuclear medicine processes provide help in diagnosing diseases with precise and detailed results at an early stage, long before the symptoms occur. Nuclear medicine tests entails less pain and offers information regarding specific organs with very little radiation. This aids the physicians to treat illnesses such as thyroid, cancer and bone metastasis.
The diagnostics segment has sub-segments that are known as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The SPECT segment is likely to dominate the radiopharmaceutical/nuclear medicine diagnostics market in the future owing to the reduced costs and greater availability.
The therapeutics segment is further classified into alpha emitters, beta emitters, and brachytherapy isotopes. The beta emitters will be the foremost segment in the radiopharmaceutical therapeutics and nuclear medicine market.
Some of the players operating in the radiopharmaceuticals and nuclear medicine market includes Cardinal Health Inc. Lantheus Medical Imaging Inc., GE Healthcare, Eczacibasi-Monrol Nuclear Products, IBA Molecular Imaging, Bayer Healthcare, Nordion Inc, Bracco Imaging S.p.A, Advanced Accelerator Applications S.A.
Nuclear Medicine or Radiopharmaceuticals Market Segmentation:
By Type
By Application
By Procedural Volume
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Nuclear Medicine or Radiopharmaceuticals Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Nuclear Medicine or Radiopharmaceuticals Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Nuclear Medicine or Radiopharmaceuticals Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Nuclear Medicine or Radiopharmaceuticals Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Nuclear Medicine or Radiopharmaceuticals Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Diagnostic Nuclear Medicine 7.1.1. Spect Radiopharmaceuticals 7.1.1.1. Tc-99m 7.1.1.2. Tl-201 7.1.1.3. Ga-67 7.1.1.4. I-123 7.1.1.5. Other Spect Isotopes 7.1.2. Pet Radiopharmaceuticals 7.1.2.1. F-18 7.1.2.2. Ru-82 7.1.2.3. Other Pet Isotopes 7.2. Therapeutic Nuclear Medicine 7.2.1. Alpha Emitters 7.2.1.1. Ra-223 7.2.1.2. Beta Emitters 7.2.1.3. I-131 7.2.1.4. Y-90 7.2.1.5. Sm-153 7.2.1.6. Re-186 7.2.1.7. Lu-177 7.2.1.8. Other Beta Emitters 7.2.2. Brachytherapy Isotopes 7.2.2.1. I-125 7.2.2.2. Ir-192 7.2.2.3. Pd-103 7.2.2.4. Cs-131 7.2.2.5. Other Brachytherapy Isotopes 8. Global Nuclear Medicine or Radiopharmaceuticals Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Diagnostic Applications 8.1.1. Spect Applications 8.1.1.1. Cardiology 8.1.1.2. Lymphoma 8.1.1.3. Neurology 8.1.1.4. Thyroid 8.1.1.5. Other Spect Applications 8.1.2. Pet Applications 8.1.2.1. Oncology 8.1.2.2. Cardiology 8.1.2.3. Neurology 8.1.2.4. Other Pet Applications 8.3. Therapeutic Applications 8.3.1. Thyroid 8.3.2. Bone Metastasis 8.3.3. Lymphoma 8.3.4. Endocrine Tumors 8.3.5. Other Therapeutic Applications 9. Global Nuclear Medicine or Radiopharmaceuticals Market, By Procedural Volume Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Diagnostic Procedures 9.1.1. Spect Radiopharmaceuticals 9.1.2. Pet Radiopharmaceuticals 9.2. Therapeutic Procedures 9.2.1. Beta Emitters 9.2.2. Alpha Emitters 9.2.3. 10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2020-2027 12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2020-2027 13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. Cardinal Health Inc. 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Lantheus Medical Imaging Inc. 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. GE Healthcare 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Eczacibasi-Monrol Nuclear Products 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 IBA Molecular Imaging 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Bayer Healthcare 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Nordion Inc 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Bracco Imaging S.p.A 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Advanced Accelerator Applications S.A. 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics